We submitted our new multi-product high potency unit at Billingham for the award (we refer to it as MF3) and it was recognized as the winner against entries from USA, Ireland, Australia, Brazil, Singapore and UK.

High potency biologics-based medicines will become an increasingly important source of new pharmaceuticals, offering higher efficacy at lower doses while reducing side effects. Demanding regulatory constraints on these types of drugs have traditionally led producers to build facilities dedicated to single products, increasing the barrier-to-entry and ultimately preventing the production of potentially life-changing therapeutics. Using a new engineering and operational approach, Fujifilm has developed a multi-product facility that uses novel technology for containment and assured degradation. This ensures there is a world class facility providing long-term opportunities for the manufacture of these important medicines.

We support our customers through the application of good science, our knowledge of the clinical process and our quality driven approach. For inquiries on How We Can Help, contact FUJIFILM Diosynth by completing this form:

*

*

*

*

I AGREE*

By submitting this form I agree that FUJIFILM Diosynth Biothechnologies may process my data in the manner described in FUJIFILM's Privacy Policy

Important Cookie Information – This message will appear only once.
FUJIFILM Diosynth websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them, please see our Privacy Policy